Generic drug development includes conducting Patient PK endpoint studies and also provide support to generic companies for the independent monitoring of the typical BA/BE studies. Patient PK endpoint studies are one of the most logistically challenged studies and requires a lot of planning. High level of enrollment rates combined with most stringent compliance factors as required for in-house studies. At PhaseON, we do have access to such specialized sites and have in-house expertise to ensure that the highest standards of quality and compliance are maintained. Our highly trained teams are supported by very extensive and stringent in-house SOPs for the monitoring of the patient PK studies and BA/BE studies.